Stroke is common, serious, and expensive. With the advent of a proven therapy for acute ischemic stroke as well as specific beneficial care processes and stroke prevention measures, there has been a groundswell of interest in developing stroke centers. The Joint Commission (formerly Joint Commission on Accreditation of Healthcare Organizations) has adopted stroke centers as a disease-specific initiative to oversee quality stroke care in America. Several states have initiated state-based designation procedures and policies. This chapter reviews the medical and financial issues related to the development of stroke centers, practical information for developing a stroke center at one's local hospital, and resources available to support this effort.
Relationship Disclosure: Dr Levine has received personal compensation for activities with AstraZeneca and as an expert in medical legal cases. Dr Levine has received personal compensation in an editorial capacity for Stroke Clinical Updates and MedLink. Dr Adamowicz has nothing to disclose. Dr Johnston has received personal compensation for activities with AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Diffusion Pharmaceuticals LLC, NIH-National Institute of Neurological Disorders and Stroke, Ono Pharmaceutical Co., Ltd, Remedy Pharmaceuticals, and sanofi-aventis. Dr Johnston has received personal compensation in an editorial capacity from Up-to-Date.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Levine discusses the unlabeled use of experimental therapies for stroke. Dr Adamowicz has nothing to disclose. Dr Johnston discusses the unlabeled use of investigational therapies.